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chronous BC was diagnosed in 13 (12%) patients, and the 
median follow-up was 21 months (interquartile range 4–48). 
Urethral cancers were of higher grade in patients with syn-
chronous BC compared to patients with non-synchronous 
BC (p = 0.020). Patients with synchronous BC exhibited sig-
nificantly inferior 3-year recurrence-free survival (RFS) com-
pared to patients with non-synchronous BC (63.2 vs. 34.4%; 
p = 0.026). In multivariable analysis, inferior RFS was associ-
ated with clinically advanced nodal stage (p < 0.001), proxi-
mal tumor location (p  < 0.001) and synchronous BC (p  = 
0.020).  Conclusion: The synchronous presence of BC in pa-
tients diagnosed with urethral carcinoma has a significant 
adverse impact on RFS and should be an impetus for a mul-
timodal approach.  © 2016 S. Karger AG, Basel 
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 Abstract 
 Introduction: The study aimed to investigate oncological 
outcomes of patients with concomitant bladder cancer (BC) 
and urethral carcinoma.  Methods: This is a multicenter series 
of 110 patients (74 men, 36 women) diagnosed with urethral 
carcinoma at 10 referral centers between 1993 and 2012. Ka-
plan–Meier analysis was used to investigate the impact of BC 
on survival, and Cox regression multivariable analysis was 
performed to identify predictors of recurrence.  Results: Syn-
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 Introduction 
 According to European cancer registries, urethral car-
cinoma is a very rare malignancy. It accounts for well un-
der 1% of all malignancies, with an estimated incidence 
of 650 new cases per year and an age-standardized ratio 
of approximately 2–5 per million in men and 0.6–2 per 
million in women  [1, 2] .
 Given the fact that tumors of the lower urinary tract 
may arise from different locations within the urinary 
tract, there is currently no data regarding the prognostic 
significance of concomitant bladder and urethral cancer 
as compared to those patients with urethral carcinoma 
only  [3] . With regard to the significantly higher incidence 
of bladder cancer (BC), the question arises as to whether 
synchronous BC impacts the prognosis of patients with 
urethral carcinoma  [3, 4] .
 In order to develop tailored treatment pathways and 
optimize the management of patients with urethral carci-
noma  [3] , the effect of synchronous BC on the prognosis 
of patients with urethral cancer needs to be better under-
stood. For this reason, we have assembled a multi-insti-
tutional collaborative with the aim of determining the 
prognostic impact of concomitant BC in patients diag-
nosed with urethral carcinoma.
 Patients and Methods 
 This is a retrospective study representing data from 10 interna-
tional academic centers. The study was approved by the indepen-
dent ethics committee at Tübingen (protocol number: 469/2015BO2) 
and participating sites. A computerized database was generated to 
combine the different data sets. Through regular communication 
with all sites, resolution of all identified anomalies was achieved be-
fore the analyses were performed. We collected data from a total of 
133 consecutive patients treated for urethral carcinoma between 
1993 and 2012. A total of 23 patients (17.3%) with evidence of dis-
tant metastatic disease at initial diagnosis were excluded from the 
final analysis. Furthermore, patients with a diagnosis of BC prior to 
the detection of urethral carcinoma or those with secondary urethral 
recurrence after radical cystectomy were excluded from this study.
 Clinical and Histologic Assessment 
 We assessed the following clinical and pathologic parameters: age 
at primary treatment, gender, clinical and pathologic tumor stage, 
clinical and histopathologic lymph node (LN) involvement, histo-
logic subtype, tumor grade, lymphovascular invasion, soft-tissue 
surgical margin (STSM) status, tumor location (proximal vs. distal), 
prior history of malignancy, modality of primary  treatment, periop-
erative chemotherapy, preoperative serum creatinine level and the 
presence of synchronous BC at diagnosis of urethral carcinoma.
 Clinical staging was based on preoperative bimanual examina-
tion, cystoscopy with biopsy and cross-sectional imaging. Histo-
logic assessment was performed at the center-specific pathology 
department and was based on the 1973 WHO grading system and 
2002 TNM classification as approved by the AJCC  [5] . The patho-
logic macro- and microscopic evaluation of specimens included 
cross-sectioning of the entire specimen with immunohistochemi-
cal staining to identify the presence of urothelial, squamous cell 
and adenocarcinoma or any other histological variant  [6] .
 Treatment Approach 
 The overall majority of patients underwent surgery for primary 
treatment while only a small proportion of them were treated with 
radiotherapy and/or chemotherapy only ( table  1 ). Regional LN 
dissection (LND) was performed at the discretion of the treating 
surgeon based on intraoperative findings and preoperative imag-
ing. The level of LND was dependent on the location of the pri-
mary tumor, encompassing the inguinal LN, external and internal 
iliac, obturator and common iliac LN.
 Follow-Up 
 Electronic hospital charts and physician records were reviewed 
to determine clinical outcomes. Due to the rarity of the disease, no 
standardized follow-up existed across all centers. Typically, fol-
low-up consisted of physical examination with laboratory testing, 
intravenous pyelography, cystoscopy, urine cytology, urethral 
washings, cross-sectional imaging and bone scintigraphy, if indi-
cated. Recurrence was defined as disease recurrence locally in the 
urethra and/or in LN and/or in distant organs.
 Statistical Analysis 
 For univariate analyses, chi-square and Fisher’s exact tests were 
used for nominal data and Student’s t test for scaled data. Kaplan–
Meier analysis with log-rank testing was employed to investigate 
the impact of the presence of synchronous BC on recurrence-free 
survival (RFS) and overall survival (OS). For determining RFS/OS, 
clinical outcomes were measured from the date of primary treat-
ment to the date of first documented recurrence/death  [7] .
 For multivariable analysis, Cox proportional hazards regres-
sion was carried out to evaluate predictors of recurrence. p values 
are two-sided and p < 0.05 was considered significant. Statistical 
analysis was performed using JMP ® 11.0. Values are given as 
mean, median and interquartile range (IQR).
 Results 
 The clinical and histopathologic tumor and patient 
characteristics are listed in  table 1 . The histological char-
acteristics of BC are listed in  table  2 . Primary urethral 
cancers were of higher grade in patients with synchro-
nous BC compared to patients with non-synchronous BC 
(p = 0.020). No further significant differences were found 
between the 3 groups. In the 51 patients who underwent 
LND in addition to primary tumor treatment, the median 
number of retrieved LN was 17 (IQR 13–21).
 The location of recurrences in the 110 patients is out-
lined in  table 1 . With a median follow-up of 21 months 
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Table 1.  Clinical and pathologic characteristics for cM0 urethral carcinoma in the 110 patients according to the 
timing of BC diagnosis
No BC Synchronous BC Metachronous BC p value
Number of patients, % 96 (87.2) 13 (11.8) 1 (0.9)
Gender 0.56
Male 63 (65.6) 10 (76.9) 1
Female 33 (34.4) 3 (23.1) 0
Age, years 0.15
Median 66 72
IQR 58–77 65–81 72
cT stage 0.32
cTX 1 (1.0) 2 (15.4) 0
cTa 12 (12.5) 2 (15.4) 1
cTis 6 (6.3) 0 (0) 0
cT1 32 (33.3) 5 (38.5) 0
cT2 23 (24.0) 3 (23.1) 0
cT3 18 (18.8) 0 (0) 0
cT4 4 (4.2) 1 (7.7) 0
pT stage 0.21
pT0 1 (1.1) 2 (15.4) 0
pTa 12 (13.5) 1 (7.7) 0
pTis 8 (9.0) 1 (7.7) 0
pTis (pu) 3 (3.4) 2 (15.4) 0
pTis (pd) 3 (3.4) 0 (0) 0
pT1 13 (14.6) 1 (7.7) 1
pT2 20 (22.5) 3 (25.0) 0
pT3 16 (18.0) 1 (7.7) 0
pT4 13 (14.6) 1 (7.7) 0
cN stage 0.72
cNX 8 (8.3) 2 (15.4) 0
cN0 76 (79.2) 11 (84.6) 1
cN+ 12 (12.5) 0 (0) 0
pN stage 0.83
pNX 41 (47.1) 8 (61.5) 1
pN0 38 (43.7) 0 (0) 0
pN1 2 (2.3) 0 (0) 0
pN2 6 (6.9) 5 (38.5) 0
Tumor grade 0.020
G1 9 (9.4) 0 0
G2 25 (26.0) 1 (7.7) 0
G3 54 (56.3) 10 (76.9) 0
GX 7 (7.3) 1 (7.7) 1
Not available 1 (1.0) 1 (7.7) 0
Histology 0.67
UC 41 (42.7) 8 (61.5) 1
SCC 28 (29.2) 2 (15.4) 0
AC 14 (14.6) 1 (7.7) 0
Mixed (UC ± SCC ± AC) 7 (7.3) 1 (7.7) 0
Leiomyosarcoma 1 (1.0) 0 (0) 0
Melanoma 2 (2.1) 0 (0) 0
Adenoid cystic carcinoma 1 (1.0) 0 (0) 0
Sarcomatoid 0 (0) 0 (0) 0
Undifferentiated 0 (0) 1 (7.7) 0
Other 2 (2.1) 0 (0) 0
Tumor location 0.18
Proximal 51 (53.1) 10 (76.9) 1
Distal 45 (46.9) 3 (23.1) 0
Prior history of malignancy 0.07
Present 19 (19.8) 5 (38.5) 1
Absent 77 (80.2) 8 (61.5) 0
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No BC Synchronous BC Metachronous BC p value
Per cancer entity
Prostate 8 (8.3) 3 (23.1) 1
Breast 3 (3.2) 0 (0) 0
Lung 1 (1.0) 0 (0) 0
Colorectal 3 (3.2) 0 (0) 0
Kidney 1 (1.0) 1 (7.7) 0
Testicular 1 (1.0) 0 (0) 0
Vulvar 2 (2.1) 0 (0) 0
Vaginal 1 (1.0) 0 (0) 0
Uterus 1 (1.0) 0 (0) 0
Oropharyngeal 1 (1.0) 0 (0) 0
Lymphoma 0 (0) 1 (7.7) 0
Pretreatment serum creatinine level, mg/dl 0.09
Median 1 1.3 0.7
Mean 1.0 1.3
IQR 0.8–1.2 1.0–1.6
Modality of primary treatment 0.45
Transurethral resection 27 (28.1) 4 (30.8) 0
Transurethral laser resection 1 (1.0) 0 (0) 0
Partial urethrectomy 7 (7.3) 0 (0) 0
Urethrectomy 25 (26.0) 1 (7.7) 1
Prostatectomy 0 (0) 0 (0) 0
Cyst(oprostat)ectomy plus urethrectomy 29 (30.2) 7 (53.8) 0
Radiotherapy 2 (2.1) 0 (0) 0
Chemotherapy 0 (0) 1 (7.7) 0
Chemoradiotherapy 3 (3.2) 0 (0) 0
Other 2 (2.1) 0 (0) 0
Perioperative chemotherapy 0.61
Neoadjuvant 9 (9.4) 2 (15.4) 1
Neoadjuvant plus adjuvant 4 (4.2) 0 (0) 0
Adjuvant 14 (14.6) 3 (23.1) 0
None 69 (71.8) 8 (61.5) 0
Location of recurrence 0.55
LN 10 (10.4) 4 (30.8) 0
Distant 2 (2.1) 1 (7.7) 0
Urethral 16 (16.7) 3 (23.1) 0
LN plus distant 6 (6.3) 0 (0) 1
LN plus urethral 3 (3.1) 0 (0) 0
Distant plus urethral 4 (4.2) 0 (0) 0
LN plus distant plus urethral 6 (6.3) 0 (0) 0
No recurrence 49 (51.0) 5 (38.5) 0
STSM 0.43
pR0 56 (58.3) 6 (46.2) 1
pR1 9 (9.4) 0 (0) 0
pR2 4 (4.2) 1 (7.7) 0
pRX 10 (10.4) 2 (15.4) 0
Not available 17 (17.7) 4 (30.8) 0
Lymphovascular invasion 0.43
LV0 22 (22.9) 5 (38.5) 0
LVI 14 (14.6) 0 (0) 0
LVX 38 (39.6) 6 (46.2) 1
Not available 22 (22.9) 2 (15.4) 0
 AC = Adenocarcinoma; pu = prostatic urethra; pd = prostatic ducts; UC = urothelial carcinoma.
No significant differences obtained when patients with metachronous disease was added to the group of pa-
tients with BC.
Table 1. (continued)
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(mean 32, IQR 4–48), recurrences occurred in 56 of the 
110 patients (50.9%). The corresponding 3- and 5-year 
RFS rates were 60.5 and 45.3%, respectively. A total of 26 
(23.6%) of the 110 patients died of other causes during the 
follow-up period, with a corresponding 3-year OS of 
78.7%. Patients with synchronous BC exhibited signifi-
cantly inferior 3-year RFS compared to patients with non-
synchronous BC (63.2 vs. 34.4%; p = 0.026;  fig. 1 ) with a 
trend toward inferior 3-year OS also approaching statisti-
cal significance (80.0 vs. 70.0%; p = 0.07). In patients with 
synchronous BC, receipt of perioperative chemotherapy 
(either given neoadjuvantly or adjuvantly) was not associ-
ated with a difference in 3-year OS (60%) compared to pa-
tients who did not receive chemotherapy (47.6%; p = 0.87).
 In the univariate Cox regression analyses, recurrence 
was significantly associated with the presence of synchro-
nous BC (p = 0.05), histopathologically advanced tumor 
Synchronous
BC
Metachronous
BC
Number of patients, % 13 1
cT stage (BC)
cTX 1 (7.7) 0
cTa 2 (15.4) 0
cTis 0 (0) 0
cT1 2 (15.4) 1
cT2 6 (46.2) 0
cT3 1 (7.7) 0
cT4 1 (7.7) 0
pT-stage (BC)
pTX 1 (7.7) 0
pT0 0 (0) 0
pTa 1 (7.7) 0
pTis 1 (7.7) 0
pT1 2 (15.4) 1
pT2a 5 (38.5) 0
pT2b 1 (7.7) 0
pT3a 1 (7.7) 0
pT3b 0 (0) 0
pT4a 1 (7.7) 0
pT4b 0 (0) 0
pN stage (BC)
pNX 3 (23.1) 0
pN0 10 (76.9) 1
pN1 0 (0) 0
pN2 0 (0) 0
pN3 0 (0) 0
Tumor grade
G1 0 (0) 0
G2 0 (0) 0
G3 12 (92.3) 0
GX 1 (7.7) 1
Synchronous
BC
Metachronous
BC
Histology
UC 10 (77.0) 1
SCC 2 (15.4) 0
AC 0 (0) 0
Undifferentiated 1 (7.7) 0
Location of BC
Lateral 5 (18.5) 0
Anterior 0 (0) 0
Posterior 1 (3.7) 0
Dome 0 (0) 0
Trigone 1 (3.7) 0
Floor 3 (11.1) 0
Left orifice 0 (0) 0
Right orifice 0 (0) 0
Neck 5 (18.5) 1
Unifocal 8 (29.6) 1
Multifocal 4 (14.8) 0
STSM
pR0 9 (69.2) 1
pR1 0 (0) 0
pR2 0 (0) 0
pRX 4 (30.8) 0
Lymphovascular invasion
LV0 7 (53.8) 0
LVI 1 (7.7) 0
LVX 5 (38.5) 1
 AC = Adenocarcinoma; SCC = squamous cell carcinoma; UC = 
urothelial carcinoma.
Table 2.  Clinical and pathologic BC characteristics in the 14 patients with urethral carcinoma
 Fig. 1. Kaplan–Meier analysis for RFS in the 110 patients staged 
cM0 according to the presence of synchronous vs. non-synchro-
nous/no BC (p = 0.026). 
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stage ( ≥ pT3; p = 0.004), clinically and histopathologically 
confirmed node-positive disease (p  = 0.001 and p  = 
0.026), proximal tumor location (p = 0.003) and positive 
STSM (p = 0.008). No significant associations were found 
between recurrence and age, gender, clinical tumor stage, 
tumor grade, prior history of another malignant disease, 
pretreatment serum creatinine levels, lymphovascular in-
vasion and histological subtype ( table 2 ).
 In the univariate analyses for OS, histopathologically 
advanced tumor stage (p = 0.019), clinically and histo-
pathologically node-positive disease (cN+ vs. cNX, p = 
0.014; pN+ vs. pNX, p = 0.017), proximal tumor location 
(p  = 0.036), STSMs (p  = 0.042) and tumor grade (p  = 
0.022) were all associated with an increased risk of death. 
No significant associations were found between overall 
mortality and lymphovascular invasion (p = 0.07), clini-
cal tumor stage, age, synchronous presence of BC, gender, 
prior history of malignant disease, pretreatment serum 
creatinine levels and histology ( table 3 ).
 In the multivariable Cox regression analysis, recur-
rence was significantly associated with clinically node-
positive disease and proximal tumor location (both p < 
0.001), as well as the presence of synchronous BC at the 
time of primary treatment (p = 0.020;  table 4 ).
 Discussion 
 Since urethral cancer is a rare tumor entity, the prog-
nostic significance of clinical and pathologic risk factors 
prior to initiation of treatment is uncertain. As the in-
cidence of BC is relatively much higher, the impact of 
Table 3.  Univariate Cox regression analysis for RFS and OS in the 110 patients with cM0 primary urethral carcinoma according to clin-
ical and pathologic tumor characteristics
Parameter RFS  OS
RR (95% CI) p value R R (95% CI) p value
Synchronous BC vs. no synchronous BC 2.29 (1.00–4.64) 0.05 2.63 (0.75–7.16) 0.11
Pathological tumor stage
≥pT3 vs. ≤pT2 2.38 (1.32–4.19) 0.004 3.01 (1.21–7.31) 0.019
Pathologic nodal stage
pN+ vs. pN0 3.22 (1.16–7.69) 0.026 2.82 (0.63–9.38) 0.15
pN+ vs. pNX 3.36 (1.21–8.13) 0.022 7.78 (1.49–36.80) 0.017
Clinical tumor stage
≥cT3 vs. ≤cT2 1.66 (0.85–3.06) 0.13 1.74 (0.62–4.25) 0.26
Clinical nodal stage
cN+ vs. cN0 4.09 (1.96–7.91) 0.001 3.47 (0.98–9.74) 0.053
cN+ vs. cNX 5.38 (1.44–34.82) 0.010 127.63 (4.98–3,279.10) 0.008
Tumor location
Proximal vs. distal 2.89 (1.31–4.21) 0.003 2.44 (1.06–6.30) 0.036
Tumor grade
G1/G2 vs. G3 1.36 (0.74–2.61) 0.33 3.14 (1.16–10.93) 0.022
Histology
UC vs. non-UC 1.01 (0.59–1.75) 0.95 1.02 (0.44–2.43) 0.96
Gender
Male vs. female 1.27 (0.72–2.33) 0.42 0.82 (0.37–1.90) 0.63
Age, years
≥65 vs. <65 1.62 (0.86–3.11) 0.13 1.18 (0.51–2.82) 0.69
Serum creatinine level
Continuously coded (total risk range) 1.28 (0.42–3.59) 0.65 0.70 (0.04–9.73) 0.80
Elevated vs. normal 0.79 (0.37–1.96) 0.58 0.74 (0.29–2.29) 0.57
Prior history of malignancy
Present vs. absent 1.55 (0.75–3.04) 0.23 2.09 (0.81–5.17) 0.12
STSM
pR0 vs. pR+ vs. pRX 18.47 (3.70–77.80) 0.008 29.84 (3.47–257.19) 0.042
Lymphovascular invasion
LVI vs. LV0/X 1.69 (0.76–3.36) 0.18 2.73 (0.894–7.12) 0.07
 RR = Relative risk; UC = urothelial carcinoma. Bold values indicate statistically significant difference.
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concomitant BC in urethral carcinoma has not been 
evaluated, and no clinically meaningful prognostic 
analyses have been reported so far. We therefore set up 
a unique collaborative to determine important predic-
tors of oncologic outcomes in patients with urethral 
carcinoma and accrued a total of 110 cases with cM0 
disease.
 In the present study, only one patient developed meta-
chronous BC 41 months after primary treatment for ure-
thral carcinoma. For this reason, we included patients 
with non-synchronous BC in a single prognostic stratum 
and compared this group to patients with synchronous 
BC. We found that most patients with synchronous BC 
had high-grade urethral carcinoma and exhibited inferior 
RFS compared to patients with non-synchronous BC. 
Additionally, the majority of patients with synchronous 
BC exhibited histopathologically confirmed muscle inva-
sive disease. These findings indicate that the synchronous 
presence of both malignant diseases exerts a markedly ad-
verse impact on outcomes. In addition, we found that ap-
proximately one-fourth of the patients in this cohort had 
a history of another malignancy, with prostate cancer be-
ing the most common. However, we did not observe an 
adverse impact of prior malignancy on RFS or OS. As this 
series is retrospective, we cannot accurately adjust for any 
causative association between the primary treatment for 
these malignancies and the carcinogenesis of urethral 
cancer.
 As would be expected, recurrence was significantly 
associated with advanced clinical nodal stage, advanced 
histopathological tumor and nodal stage, proximal tu-
mor location, STSMs and synchronous BC. These re-
sults are in accordance with prior studies  [2, 8, 9] . For 
the multivariable analysis, we included all significant pa-
rameters from the univariate analyses that correlated 
with survival. Clinical nodal stage, tumor location and 
presence of synchronous BC were the only parameters 
found to be independently associated with RFS. Impor-
tantly, we recently reported that clinical nodal stage is a 
strong predictor for outcomes in primary urethral can-
cer  [10] . As the number of events was low (n = 26 death 
events), we did not perform a multivariable analysis for 
OS.
 This study has limitations inherent to its retrospective 
and multi-center design, which is requisite given the rar-
ity of urethral carcinoma. Although we included patients 
treated at academic centers within the last 20 years, the 
number of included patients and follow-up period is lim-
ited due to the rarity and aggressiveness of the disease. 
Further potential biases include the absence of LND in 
approximately half of the patients and interobserver vari-
abilities in the clinical staging and histopathologic assess-
ment of specimens. In addition, adjustments for patient 
preferences, toxicities and side effects of primary treat-
ment as well as comorbidities could not be taken into ac-
count.
Table 4.  Multivariate analysis for predicting recurrence in the 110 patients with cM0 bladder and urethral carcinoma
Variable Full model  Final model
regression 
coefficient
HR (95% CI) p value regress ion 
coefficient
HR (95% CI) p value
BC
Synchronous vs. no BC/metachronous BC 0.795 4.91 (1.30–17.71) 0.020 0.383 2.14 (1.00–4.54) 0.05
Tumor location
Proximal vs. distal 1.094 8.93 (3.07–33.70) <0.001 0.486 2.64 (1.45–5.05) 0.001
Clinical nodal stage
cN+ vs. cN0 vs. cNX 1.285 13.08 (3.40–50.61) <0.001 0.926 6.37 (2.93–13.07) <0.001
Tumor grade
G3 vs. G1/G2 0.475 2.59 (0.93–7.58) 0.068
Pathologic tumor stage
≥pT3 vs. ≤pT2 0.348 2.00 (0.73–5.34) 0.17
Lymphovascular invasion
LVI vs. LV0 vs. LVX 0.685 1.98 (0.58–6.79) 0.27
STSMs
pR+ vs. pR0 vs. pRX 0.227 1.25 (0.27–6.29) 0.74
 HR = Hazards ratio.
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 We recently reported that neoadjuvant chemo(radio)
therapy also exerts a beneficial impact on outcomes in 
patients with clinically advanced primary urethral cancer 
( ≥ cT3 and or cN+)  [11] . The number of patients with 
concomitant bladder and urethral carcinoma was rather 
small (n = 13) making it difficult to draw meaningful con-
clusions on the role of neoadjuvant chemotherapy. How-
ever, only 2 of the patients with concomitant bladder and 
urethral carcinoma received neoadjuvant chemotherapy 
even though both malignancies were staged as muscle in-
vasive ( ≥ pT2 BC:  ≈ 62%;  ≥ pT2 urethral carcinoma  ≈ 56%) 
in the majority of cases. Taking the results of the multi-
variable analysis into consideration, neoadjuvant chemo-
therapy is likely an important treatment strategy for pa-
tients with concomitant bladder and urethral carcinoma 
who have clinically node-positive disease and proximal 
urethral tumors.
 As the incidence of BC is much higher compared to 
urethral cancer, one cannot exclude the possibility that 
primary BC developed first in the lower urinary tract 
which then metastasized to the urethra rather than occur-
ring synchronously. Additionally, as this report includes 
different histological subtypes of urethral carcinoma, the 
tumor biology and treatment regimens may have impact-
ed key outcomes. Therefore, combining all these cases 
into one group carries important limitations. However, 
population-based studies have shown that the histologi-
cal subtype of urethral carcinoma does not appear to exert 
an impact on prognosis  [1, 2, 8, 9] . Nonetheless, it has to 
be acknowledged that urethral cancer is a rare disease for 
which therapeutic strategies still need to be better defined 
 [12] . Though secondary urethral cancer after RC for BC 
is more frequent than concomitant urethral and BC it is 
difficult to draw meaningful conclusions for clinical prac-
tice owing to distinct differences in tumor biologic char-
acteristics  [13] . Given this, to our opinion, our study gives 
important insights into the clinical course of patients with 
urethral carcinoma which may be further used for prog-
nostication and clinical decision-making in daily prac-
tice.
 Conclusions 
 This is the first series that has investigated the impact 
of synchronous BC on outcomes of patients with urethral 
cancer. The findings of this study highlight the impaired 
prognosis of these patients and should be an impetus to 
consider a multimodal approach for the subgroup of pa-
tients with concomitant bladder and urethral cancer.
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